Endothelin: 20 Years from discovery to therapy

Matthias Barton, Masashi Yanagisawa

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence.The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.

Original languageEnglish (US)
Pages (from-to)485-498
Number of pages14
JournalCanadian Journal of Physiology and Pharmacology
Volume86
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Endothelins
Kidney Neoplasms
Clinical Medicine
Peptides
Therapeutics
Endothelin Receptors
Connective Tissue Diseases
Vasoconstrictor Agents
Endothelin-1
Pulmonary Hypertension
Patient Selection
Publications
Endothelial Cells
Heart Failure
Hypertension
Research
Genes
Clinical Studies

Keywords

  • Ambrisentan
  • Atherosclerosis
  • Bosentan
  • Congestive heart failure
  • Connective tissue disease
  • Darusentan
  • Diabetes
  • Diabetic nephropathy
  • Endothelin receptor antagonists
  • Kidney disease
  • Metabolic syndrome
  • Pulmonary hypertension
  • Scleroderma
  • Sitaxsentan

ASJC Scopus subject areas

  • Physiology
  • Pharmacology

Cite this

Endothelin : 20 Years from discovery to therapy. / Barton, Matthias; Yanagisawa, Masashi.

In: Canadian Journal of Physiology and Pharmacology, Vol. 86, No. 8, 08.2008, p. 485-498.

Research output: Contribution to journalArticle

@article{02845ef1fb704d668729acbef2a727c3,
title = "Endothelin: 20 Years from discovery to therapy",
abstract = "Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence.The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.",
keywords = "Ambrisentan, Atherosclerosis, Bosentan, Congestive heart failure, Connective tissue disease, Darusentan, Diabetes, Diabetic nephropathy, Endothelin receptor antagonists, Kidney disease, Metabolic syndrome, Pulmonary hypertension, Scleroderma, Sitaxsentan",
author = "Matthias Barton and Masashi Yanagisawa",
year = "2008",
month = "8",
doi = "10.1139/Y08-059",
language = "English (US)",
volume = "86",
pages = "485--498",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "8",

}

TY - JOUR

T1 - Endothelin

T2 - 20 Years from discovery to therapy

AU - Barton, Matthias

AU - Yanagisawa, Masashi

PY - 2008/8

Y1 - 2008/8

N2 - Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence.The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.

AB - Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence.The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.

KW - Ambrisentan

KW - Atherosclerosis

KW - Bosentan

KW - Congestive heart failure

KW - Connective tissue disease

KW - Darusentan

KW - Diabetes

KW - Diabetic nephropathy

KW - Endothelin receptor antagonists

KW - Kidney disease

KW - Metabolic syndrome

KW - Pulmonary hypertension

KW - Scleroderma

KW - Sitaxsentan

UR - http://www.scopus.com/inward/record.url?scp=48849094089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849094089&partnerID=8YFLogxK

U2 - 10.1139/Y08-059

DO - 10.1139/Y08-059

M3 - Article

C2 - 18758495

AN - SCOPUS:48849094089

VL - 86

SP - 485

EP - 498

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 8

ER -